Saturn V Capital Management L.P. is an investment fund managing more than $265 billion ran by Douglas Edwards. There are currently 26 companies in Mr. Edwards’s portfolio. The largest investments include Argenx Se and Disc Medicine Inc, together worth $50.3 billion.
As of 7th August 2024, Saturn V Capital Management L.P.’s top holding is 64,196 shares of Argenx Se currently worth over $27.6 billion and making up 10.4% of the portfolio value.
In addition, the fund holds 503,089 shares of Disc Medicine Inc worth $22.7 billion.
The third-largest holding is Crinetics Pharmaceuticals In worth $21.5 billion and the next is Vaxcyte worth $16.3 billion, with 215,680 shares owned.
Currently, Saturn V Capital Management L.P.'s portfolio is worth at least $265 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Saturn V Capital Management L.P. office and employees reside in Austin, Texas. According to the last 13-F report filed with the SEC, Douglas Edwards serves as the Chief Financial Officer at Saturn V Capital Management L.P..
In the most recent 13F filing, Saturn V Capital Management L.P. revealed that it had opened a new position in
Cargo Therapeutics Inc and bought 856,849 shares worth $14.1 billion.
The investment fund also strengthened its position in Disc Medicine Inc by buying
248,286 additional shares.
This makes their stake in Disc Medicine Inc total 503,089 shares worth $22.7 billion.
On the other hand, there are companies that Saturn V Capital Management L.P. is getting rid of from its portfolio.
Saturn V Capital Management L.P. closed its position in Apellis Pharmaceuticals Inc on 14th August 2024.
It sold the previously owned 71,463 shares for $4.2 billion.
Douglas Edwards also disclosed a decreased stake in Argenx Se by approximately 0.1%.
This leaves the value of the investment at $27.6 billion and 64,196 shares.
The two most similar investment funds to Saturn V Capital Management L.P. are Ribbit Capital Gp Ii and Mccarthy & Cox. They manage $265 billion and $265 billion respectively.
Saturn V Capital Management L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 59.2% of
the total portfolio value.
The fund focuses on investments in the United States as
50.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
4% of the total holdings value.
On the other hand, small-cap stocks make up only 3.8% of the portfolio.
The average market cap of the portfolio companies is close to $2.92 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Argenx Se |
2.14%
64,196
|
$27,606,848,000 | 10.43% |
| Disc Medicine Inc |
97.44%
503,089
|
$22,674,221,000 | 8.57% |
| Crinetics Pharmaceuticals In |
27.34%
479,681
|
$21,484,912,000 | 8.12% |
| Vaxcyte, Inc. |
16.47%
215,680
|
$16,285,997,000 | 6.15% |
| Ascendis Pharma A/S |
9.47%
113,224
|
$15,441,489,000 | 5.83% |
| Cytokinetics Inc |
3.16%
272,036
|
$14,738,910,000 | 5.57% |
| Biomarin Pharmaceutical Inc. |
49.84%
178,589
|
$14,703,232,000 | 5.56% |
| Cogent Biosciences, Inc. |
4.95%
1,673,919
|
$14,111,137,000 | 5.33% |
| Cargo Therapeutics Inc |
Opened
856,849
|
$14,069,461,000 | 5.32% |
| KalVista Pharmaceuticals Inc |
21.74%
1,128,478
|
$13,293,471,000 | 5.02% |
| Celcuity Inc |
Opened
760,941
|
$12,464,214,000 | 4.71% |
| Merus N.V |
56.25%
164,773
|
$9,749,618,000 | 3.68% |
| Syndax Pharmaceuticals Inc |
5.44%
419,654
|
$8,615,497,000 | 3.26% |
| Abivax Sa |
0.77%
627,760
|
$8,298,987,000 | 3.14% |
| Ironwood Pharmaceuticals Inc |
17.88%
1,113,824
|
$7,262,132,000 | 2.74% |
| Amicus Therapeutics Inc |
20.58%
713,536
|
$7,078,277,000 | 2.67% |
| AnaptysBio Inc |
57.41%
249,609
|
$6,255,202,000 | 2.36% |
| Phathom Pharmaceuticals Inc |
18.43%
593,306
|
$6,111,052,000 | 2.31% |
| iTeos Therapeutics, Inc. |
5.08%
367,429
|
$5,452,646,000 | 2.06% |
| Inozyme Pharma, Inc. |
Opened
1,140,310
|
$5,085,783,000 | 1.92% |
| Apellis Pharmaceuticals Inc |
Closed
71,463
|
$4,200,595,000 | |
| Neumora Therapeutics Inc. |
Opened
390,084
|
$3,834,526,000 | 1.45% |
| Geron Corp. |
Closed
1,123,995
|
$3,709,184,000 | |
| Enliven Therapeutics Inc |
Opened
152,178
|
$3,556,400,000 | 1.34% |
| Cabaletta Bio Inc |
Closed
173,173
|
$2,954,331,000 | |
| Longboard Pharmaceuticals In |
Opened
71,442
|
$1,931,077,000 | 0.73% |
| Rapport Therapeutics Inc |
Opened
70,000
|
$1,628,200,000 | 0.62% |
| Morphic Hldg Inc |
44.34%
47,660
|
$1,623,776,000 | 0.61% |
| Contineum Therapeutics Inc |
Opened
72,831
|
$1,282,554,000 | 0.48% |
| No transactions found | |||
| Showing first 500 out of 29 holdings | |||